You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奇正藏藥(002287.SZ):子公司收到小兒熱立清顆粒藥物臨牀試驗批准通知書
格隆匯 05-28 16:54

格隆匯5月28日丨奇正藏藥(002287.SZ)公佈,近日,西藏奇正藏藥股份有限公司子公司奇正(珠海市橫琴)國際醫藥有限公司、甘肅奇正藏藥有限公司收到國家藥品監督管理局簽發的小兒熱立清顆粒的《藥物臨牀試驗批准通知書》。

小兒熱立清顆粒處方來源於全國名中醫張士卿教授的臨牀經驗方,具有多年的臨牀使用歷史,功能主治為解熱透表,化濕和胃,用於急性上呼吸道感染(感冒風熱夾濕證)。

臨牀前主要藥效學研究顯示,小兒熱立清顆粒對內毒素誘導家兔發熱模型、酵母致大鼠發熱模型具有明顯解熱作用;對枸櫞酸致豚鼠咳嗽具有明顯的延長誘咳潛伏期、減少咳嗽次數;對二甲苯誘導的急性滲出性炎症有明顯的抗炎作用;具有顯著提高小鼠氣管灌洗液中苯酚紅含量。毒理學研究顯示,小兒熱立清顆粒藥物安全性好,安全劑量範圍較寬。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account